2025-01-31 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison & Divergence:**

Eli Lilly and Co (LLY), a leading pharmaceutical company specializing in diabetes treatments, oncology, and other therapeutic areas, significantly outperformed the S&P 500 (VOO) over the observed period.  The cumulative return for LLY is 599.11%, while VOO's is 121.09%.  The difference in cumulative returns is a substantial 478.01%.  This places LLY at the 76.3rd percentile of its historical relative performance against the S&P 500, indicating a strong outperformance, according to the provided data.  The provided alpha values of 0.0 throughout the given periods, however,  suggest that this outperformance may not be entirely attributable to factors beyond market movements.  More detailed alpha analysis using a different model might be necessary.

**2. Recent Price Movement:**

* **Closing Price:** $823.23
* **5-Day Moving Average:** $805.18
* **20-Day Moving Average:** $775.94
* **60-Day Moving Average:** $783.84

The recent closing price is above all three moving averages, suggesting a short-term uptrend.  The substantial difference between the 5-day and 60-day moving average indicates considerable momentum. The price increase of $19.15 from the previous close ($804.08) signals a significant daily increase, potentially indicating a period of rapid upward movement.

**3. Technical Indicators & Expected Return:**

* **RSI:** 58.26 (Slightly above neutral; not overbought)
* **PPO:** 0.9978 (Positive, indicating bullish momentum)
* **20-Day Relative Divergence:** +7.6 (Short-term upward trend confirmed)
* **Expected Return (2+ years):** 107.7% (Significant outperformance of the S&P 500 is expected, assuming consistent performance, a long-term perspective, and the reliability of this prediction).  This should be considered a long-term outlook only.

The technical indicators suggest a positive short-term outlook, with a relatively strong but not extreme bullish momentum.  The significant daily price increase highlights recent market activity, warranting further investigation into potential catalysts.

**4. Recent Earnings Analysis:**

The earnings data shows some volatility:

| Date       | EPS    | Revenue      | Notes                                   |
|------------|--------|--------------|----------------------------------------|
| 2024-10-30 | $1.08  | $11.44B      |                                        |
| 2024-08-08 | $3.29  | $11.30B      |                                        |
| 2024-04-30 | $2.49  | $8.77B       |                                        |
| 2023-11-02 | -$0.06 | $9.50B       |                                        |
| 2024-10-30 | -$0.06 | $9.50B       | Duplicate entry, likely a data error. |


There's a noticeable fluctuation in EPS, requiring further investigation into underlying factors. The duplicate entry needs clarification.

**5. Financial Information:**

**Revenue and Profitability:**  Revenue shows some fluctuation, but generally remains strong.  Profit margins are consistently high (above 80%), indicating strong profitability.

**Capital and Profitability:** Equity is growing.  ROE shows considerable variation, highlighting potential volatility in profitability. The negative ROE in 2023-09-30 needs further analysis.


**7. Overall Analysis:**

LLY has significantly outperformed the S&P 500, showcasing strong growth.  Technical indicators suggest a positive short-term outlook, though RSI is not extreme.  Recent earnings show volatility requiring further investigation.  High and consistent profit margins are positive.  The large divergence from the S&P 500 warrants further due diligence and understanding of potential market factors affecting LLY's performance before any investment decisions.  The extremely high expected return needs to be treated with caution;  it is a prediction based on past performance, which is not an indicator of future results.  Investigating the reasons behind the large fluctuations in EPS and ROE is critical for a comprehensive risk assessment.  The duplicated data entry requires correction and explanation.
